-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China is a big country with diabetes and a large number of patients.
Insulin is an important drug for diabetes patients to control blood sugar and has an irreplaceable position in the treatment of diabetes
.
According to Meinenet data, the insulin drug market in China's public hospitals will be close to 27 billion yuan in 2020
.
However, due to the long-term use of insulin, the price gap between different brands ranges from tens of yuan to hundreds of yuan.
The inflated price is a heavy burden for patients
.
According to data from the International Diabetes Federation (IDF) in November 2021, approximately 141 million adults in China suffer from diabetes, and diabetes-related medical expenditures are as high as US$165.
3 billion
.
Nowadays, diabetic patients are finally ushering in the gospel.
With the promotion of the sixth batch of insulin special collection, 140 million diabetic patients in China will enjoy nearly half the price of insulin medicines
.
On November 26th, the sixth batch of national procurement was opened in Shanghai.
This national procurement covers the second- and third-generation insulins commonly used in clinics, covering the needs of 32,000 medical institutions, and the purchase amount involved is about 16.
1 billion yuan
.
The 11 companies participating in the centralized drug procurement bidding are divided into three camps.
The first team is the three multinational pharmaceutical companies occupying more than 70% of the market, including Novo Nordisk, Sanofi and Eli Lilly; the first team is the recent fast The growing domestic giant pharmaceutical companies, including Ganli Pharmaceutical, Tonghua Dongbao and Zhuhai Federation, account for nearly 30% of the market share; another team is Jiangsu Wanbang, Hefei Yifan, Hefei Tianmai, Zhejiang Haizheng, Yichang Dongyangguang Waiting for new entrants
.
Judging from the procurement results, the average price of the selected products in this centralized procurement will be reduced by 48%, which is expected to save 9 billion yuan each year
.
Among them, the three multinational giants Novo Nordisk, Sanofi, and Eli Lilly have been selected for their products, and the average decline of the three is 41%, 52%, and 44% respectively
.
Among them, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection reported 18.
89 yuan, a drop of more than 73%, which can be described as a substantial price cut
.
Among domestic manufacturers, Tonghua Dongbao’s 5 winning bid products dropped by an average of 41%; among the 6 selected products from Ganli Pharmaceutical, among them, protamine and human insulin mixed injection (30R), insulin glargine and insulin aspart, the price reduction rate 64%, 72% and 63% respectively
.
In addition, Dongyang Sunshine, Tianmai Biological, Hisun Pharmaceutical, and Dongyang Sunshine also won bids for their products through price cuts
.
In fact, the introduction of insulin into the country is expected
.
In January 2020, the Wuhan Medical Insurance Bureau tried to purchase insulin in quantities.
In this centralized procurement, nine companies including Novo Nordisk, Eli Lilly, Tonghua Dongbao, Ganli Pharmaceutical and other nine companies began price reduction negotiations.
The results showed that some of them won the bid.
The unit price of insulin drugs dropped by 43%
.
More than a year has passed since the local centralized procurement, and the national procurement of insulin has only arrived.
The analysis believes that insulin is a biological product, and chemical drugs need a new set of procurement rules, so it took some time
.
Today, with the advancement of the national procurement of insulin, the market share of foreign companies in China may be affected by the opportunity for local pharmaceutical companies to "overtake"
.
"In addition, from a market perspective, insulin, as a biological product, is different from previous chemical drugs, and the competition itself is very fierce.
This time, the national procurement is a concentrated procurement of insulin, which may also test the acceptance of the market
.
" The industry believes that in addition to centralized procurement and price reductions, diabetic patients also enjoy the benefits of medical insurance reimbursement, which is expected to greatly reduce the burden of patients' drug costs in the future
.
Insulin is an important drug for diabetes patients to control blood sugar and has an irreplaceable position in the treatment of diabetes
.
According to Meinenet data, the insulin drug market in China's public hospitals will be close to 27 billion yuan in 2020
.
However, due to the long-term use of insulin, the price gap between different brands ranges from tens of yuan to hundreds of yuan.
The inflated price is a heavy burden for patients
.
According to data from the International Diabetes Federation (IDF) in November 2021, approximately 141 million adults in China suffer from diabetes, and diabetes-related medical expenditures are as high as US$165.
3 billion
.
Nowadays, diabetic patients are finally ushering in the gospel.
With the promotion of the sixth batch of insulin special collection, 140 million diabetic patients in China will enjoy nearly half the price of insulin medicines
.
On November 26th, the sixth batch of national procurement was opened in Shanghai.
This national procurement covers the second- and third-generation insulins commonly used in clinics, covering the needs of 32,000 medical institutions, and the purchase amount involved is about 16.
1 billion yuan
.
The 11 companies participating in the centralized drug procurement bidding are divided into three camps.
The first team is the three multinational pharmaceutical companies occupying more than 70% of the market, including Novo Nordisk, Sanofi and Eli Lilly; the first team is the recent fast The growing domestic giant pharmaceutical companies, including Ganli Pharmaceutical, Tonghua Dongbao and Zhuhai Federation, account for nearly 30% of the market share; another team is Jiangsu Wanbang, Hefei Yifan, Hefei Tianmai, Zhejiang Haizheng, Yichang Dongyangguang Waiting for new entrants
.
Judging from the procurement results, the average price of the selected products in this centralized procurement will be reduced by 48%, which is expected to save 9 billion yuan each year
.
Among them, the three multinational giants Novo Nordisk, Sanofi, and Eli Lilly have been selected for their products, and the average decline of the three is 41%, 52%, and 44% respectively
.
Among them, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection reported 18.
89 yuan, a drop of more than 73%, which can be described as a substantial price cut
.
Among domestic manufacturers, Tonghua Dongbao’s 5 winning bid products dropped by an average of 41%; among the 6 selected products from Ganli Pharmaceutical, among them, protamine and human insulin mixed injection (30R), insulin glargine and insulin aspart, the price reduction rate 64%, 72% and 63% respectively
.
In addition, Dongyang Sunshine, Tianmai Biological, Hisun Pharmaceutical, and Dongyang Sunshine also won bids for their products through price cuts
.
In fact, the introduction of insulin into the country is expected
.
In January 2020, the Wuhan Medical Insurance Bureau tried to purchase insulin in quantities.
In this centralized procurement, nine companies including Novo Nordisk, Eli Lilly, Tonghua Dongbao, Ganli Pharmaceutical and other nine companies began price reduction negotiations.
The results showed that some of them won the bid.
The unit price of insulin drugs dropped by 43%
.
More than a year has passed since the local centralized procurement, and the national procurement of insulin has only arrived.
The analysis believes that insulin is a biological product, and chemical drugs need a new set of procurement rules, so it took some time
.
Today, with the advancement of the national procurement of insulin, the market share of foreign companies in China may be affected by the opportunity for local pharmaceutical companies to "overtake"
.
"In addition, from a market perspective, insulin, as a biological product, is different from previous chemical drugs, and the competition itself is very fierce.
This time, the national procurement is a concentrated procurement of insulin, which may also test the acceptance of the market
.
" The industry believes that in addition to centralized procurement and price reductions, diabetic patients also enjoy the benefits of medical insurance reimbursement, which is expected to greatly reduce the burden of patients' drug costs in the future
.
